Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics.

Date publication

février 2015

Journal

Journal of vascular and interventional radiology : JVIR

Auteurs

Membres identifiés du Cancéropôle Est :
Pr SCHMITT Antonin , Dr WENDREMAIRE Maeva

Tous les auteurs :
Guiu B, Schmitt A, Reinhardt S, Fohlen A, Pohl T, Wendremaire M, Denys A, Blümmel J, Boulin M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25311967

Résumé

To present in vitro loading and release characteristics of idarubicin with ONCOZENE (CeloNova BioSciences, Inc, San Antonio, Texas) drug-eluting embolic (DEE) agents and in vivo pharmacokinetics data after transarterial chemoembolization with idarubicin-loaded ONCOZENE DEE agents in patients with hepatocellular carcinoma.

Mots clés

Aged, Antibiotics, Antineoplastic, administration & dosage, Carcinoma, Hepatocellular, blood, Chemoembolization, Therapeutic, methods, Delayed-Action Preparations, administration & dosage, Diffusion, Hemostatics, administration & dosage, Humans, Idarubicin, administration & dosage, Liver Neoplasms, blood, Male, Metabolic Clearance Rate, Polymethacrylic Acids, administration & dosage, Treatment Outcome

Référence

J Vasc Interv Radiol. 2015 Feb;26(2):262-70